R&D | February 18, 2026
Evogene and QUT join forces to tackle chemotherapy-resistant lung cancer with AI
Dr Adams’ lab recently uncovered a novel cellular detoxification pathway driving Cisplatin resistance in NSCLC
Dr Adams’ lab recently uncovered a novel cellular detoxification pathway driving Cisplatin resistance in NSCLC
DeslaFlex is an innovative antidepressant formulation developed by Spektus using the proprietary Flexitab oral drug-delivery platform
Alto met its enrollment goal with 83 patients across 13 US clinical sites
Iberdomide has the potential to be the first approved CELMoD agent
MYC, a master regulator of oncogenic transcription, drives multiple high-burden cancers but has long eluded direct pharmacologic control
Bocunebart works by blocking pituitary adenylate cyclase-activating polypeptide
ADQUEY’s approval opens the door to a new alternative for millions of Americans struggling with atopic dermatitis
PBGENE-DMD is designed to permanently correct mutations in the dystrophin gene between exons 45 and 55, the “hot-spot” region affecting roughly 60% of DMD patients
The collaboration is anchored in Syngene’s SynVent platform and Connector model to accelerate promising academic research
The acquisition brings Lilly a novel in vivo cell therapy platform built around engineered circular RNA and proprietary lipid nanoparticles
Subscribe To Our Newsletter & Stay Updated
